A randomized double-blind phase 2 study of ruxolitinib (RUX) or placebo (PBO) with capecitabine (CAPE) as second-line therapy in patients (pts) with metastatic pancreatic cancer (mPC).

Hurwitz, Herbert I.; Uppal, Nikhil; Wagner, Stéphanie; Bendell, Johanna C.; Beck, J. Thaddeus; Wade, Seaborn Mcdonald; Nemunaitis, John; Stella, Philip J.; Pipas, J. Marc; Wainberg, Zev A.; Manges, Robert; Garrett, William M.; Hunter, Deborah; Clark, Jason; Leopold, Lance; Levy, Richard S.; Sandor, Victor

doi:10.1200/jco.2014.32.15_suppl.4000

Cited by 39 publications

(22 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…113 The results of a randomized, phase II trial of capecitabine plus either ruxolitinib or placebo in the second-line treatment of patients with metastatic pancreatic cancer (RECAP) were presented at the 2014 ASCO meeting. 114 Overall, no difference in survival was observed (Table 3); however, in a pre-specified subset analysis, patients with a serum signature of systemic inflammation (determined by a modified Glasgow prognostic score incorporating serum C-reactive protein levels) had an improvement in the 6-month survival rate (42% versus 11%; HR 0.47; P = 0.01), and median survival (2.8 months versus 1.9 months; P = 0.04). Two randomized phase III trials evaluating capecitabine plus either ruxolitinib or placebo in the second-line treatment of advanced-stage PDAC, JANUS1 (NCT02117479) and JANUS2 (NCT02119663), 115,116 are currently ongoing.…”

Section: Janus Kinase Inhibitorsmentioning

confidence: 97%

Pancreatic cancer: from state-of-the-art treatments to promising novel therapies

2015

View full text Add to dashboard Cite

Pancreatic cancer is expected to be the second deadliest malignancy in the USA by 2020. The survival rates for patients with other gastrointestinal malignancies have increased consistently during the past 30 years; unfortunately, however, the outcomes of patients with pancreatic cancer have not changed significantly. Although surgery remains the only curative treatment for pancreatic cancer, therapeutic strategies based on initial resection have not substantially improved the survival of patients with resectable disease over the past 25 years; presently, more than 80% of patients suffer disease relapse after resection. Preclinical evidence that pancreatic cancer is a systemic disease suggests a possible benefit for early administration of systemic therapy in these patients. In locally advanced disease, the role of chemoradiotherapy is increasingly being questioned, particularly considering the results of the LAP-07 trial. Novel biomarkers are clearly needed to identify subsets of patients likely to benefit from chemoradiotherapy. In the metastatic setting, FOLFIRINOX (folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin), and nab-paclitaxel plus gemcitabine have yielded only modest improvements in survival. Thus, new treatments are urgently needed for patients with pancreatic cancer. Herein, we review the state-of-the-art of pancreatic cancer treatment, and the upcoming novel therapeutics that hold promise in this disease are also discussed.

show abstract

Section: Janus Kinase Inhibitorsmentioning

confidence: 97%

Pancreatic cancer: from state-of-the-art treatments to promising novel therapies

2015

View full text Add to dashboard Cite

show abstract

“…This was assessed recently in a double blind randomised phase 2 study of ruxolitinib or placebo as 2nd line therapy for patients with advanced PDAC (all patients also received oral capecitabine) and reported at the American Society of Clinical Oncology (ASCO) in June 2014 [19]. This North American multicentre study included 127 patients and showed a marginal advantage for the ruxolitinib group.…”

Section: Anti Inflammatory Drugs In Pdac Therapy ?mentioning

confidence: 97%

Host systemic inflammatory response influences outcome in pancreatic cancer

Imrie

2015

Pancreatology

View full text Add to dashboard Cite

“…The clinical utility of ruxolitinib has been established in myelofibrosis (a myeloproliferative neoplasm) in a series of landmark studies. 21 Recently, Hurwitz et al 23 reported the results, in abstract form, of a randomized double-blind phase-2 study of ruxolitinib or placebo with capecitabine as a second-line therapy in patients with metastatic pancreatic cancer. They showed that the combination was associated with improved survival particularly in those patients with an elevated circulating C-reactive protein concentration.…”

Section: Targeting Innate/humoral Immune/ Inflammatory Responsesmentioning

confidence: 98%

Therapeutics targeting innate immune/inflammatory responses through the interleukin-6/JAK/STAT signal transduction pathway in patients with cancer

Roxburgh

McMillan

2016

Translational Research

View full text Add to dashboard Cite

A randomized double-blind phase 2 study of ruxolitinib (RUX) or placebo (PBO) with capecitabine (CAPE) as second-line therapy in patients (pts) with metastatic pancreatic cancer (mPC).

Cited by 39 publications

References 0 publications

Pancreatic cancer: from state-of-the-art treatments to promising novel therapies

Pancreatic cancer: from state-of-the-art treatments to promising novel therapies

Host systemic inflammatory response influences outcome in pancreatic cancer

Therapeutics targeting innate immune/inflammatory responses through the interleukin-6/JAK/STAT signal transduction pathway in patients with cancer

Contact Info

Product

Resources

About